Datametrex Obtains Rights to Sell COVID-19 Home Test Kits With FDA Registration

Shares :

TORONTO, June 16, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured non-exclusive rights to sell RapiGEN Inc. (“RapiGEN”) COVID-19 home test kitsi. These test kits are FDA registered, suitable for point of care testing, no extra equipment is needed, and are easy to use with results in 5-10 minutes.

If the specimen contains IgM antibodies to SARS-CoV-2, a colored line appears in the T line area. The RapiGen home test kit is a lateral flow immunochromatographic assay (LFIA) for the qualitative detection of IgG antibodies to COVID19 in blood, serum or plasma specimens.

Watch the sample video of the test here: https://datametrex.com/investor/video.html

The Company’s primary goal is to sell to the current clients for their operations out of Canada, and the Company intends to apply for Health Canada approval with an Interim Order (“IO”).

“These test kits are revolutionary in expediting the process of testing since it cuts out the processing time by a fraction, aiding in an earlier detection of the virus, a more accurate prediction of the positive cases and a decrease of the infection rate,”

-said Marshall, CEO of the Company.

“Having seen the urgent need for COVID-19 test kits, Datametrex is doing everything it can to help Canada combat COVID-19 and flatten the curve. In the meantime, having FDA registration under EUA allowing us to help our neighbours to the south and any Canadian company with operations in the US and Europe,”

-says Andrew Ryu, Chairman of the Company.

The Company’s ability to fulfill any purchase order for Covid-19 test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits.

The Company is exploring oportunities with Michigan Economic Development Corporation and Governor’s Office of Business and Economic Development in California looking into retail, film, healthcare oportunities. With months into the spread of the COVID-19 in Califoria, widespread diagnostic testing still isn’t available. Testing voids, stemming from an overwhelmed supply chain and a disjointed public health system, have hit hardest in California’s rural north. The Michigan Department of Health and Human Services, Michigan State Police, and local health departments are looking to expand COVID-19 testing directly to the community. Michegan now is easing coronavirus restrictions with six-part reopening plan that includes testing to ensure the state lowers the chance of a second wave and to further protect Michigan families.

The psychedelic market | A little-known and undervalued company ahead of their peers | LOOK HERE

LAST ALERT MADE MORE THAN 800% !


This article is written and published by The Stocks market 


Disclaimer : The Stocks market does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Stocks market are engaged in the business of marketing and advertising companies.

The Stocks market and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.


Shares :